Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 21: 1368-1371, 1975;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Werner, M.
Right arrow Articles by Abramson, F. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Werner, M.
Right arrow Articles by Abramson, F. P.

Clinical Chemistry, Vol 21, 1368-1371, Copyright © 1975 by the American Association for Clinical Chemistry

Concepts for the Rational Selection of Assays to Be Used in Monitoring Therapeutic Drugs

Mario Werner 1, Earl W. Sutherland III 2, and Fred P. Abramson 3

1 Division of Laboratory Medicine, The George Washington University School of Medicine, Washington, D.C. 20037.
2 Departments of Pathology (Laboratory Medicine), Medicine and Pharmacology, The George Washington University School of Medicine, Washington, D.C. 20037.
3 Departments of Pathology (Laboratory Medicine) and Pharmacology, The George Washington University School of Medicine, Washington, D.C. 20037.

As the domain of monitoring therapeutic drugs rapidly expands from experimental investigations to everyday patient care, all clinical laboratory scientists, but especially clinical chemists, must learn to deal with their involvement in this expansion. First, the theoretical concepts underlying clinical pharmacology must be appreciated so that the laboratory's participation in it can succeed. Individual differences cause unpredictable variations of response to the customarily standardized drug dosage. Properly used, assays of drugs in blood can eliminate such variabilities. Second, the practical selection of which drug assays a laboratory intends to provide must be based on a rational evaluation of assay usefulness, integrating both clinical and laboratory considerations. Such a decision model is suggested; it is generally applicable in allocating priorities among an ever-increasing number of proposed tests under the constraint of finite resources.

Submitted on April 10, 1975
Accepted on May 30, 1975







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1975 by the American Association for Clinical Chemistry.